Fluoroscopy-only guided patent foramen ovale device closure: will it cut ice with the interventional community?
Publication date: Available online 31 March 2020Source: Canadian Journal of CardiologyAuthor(s): Anoop Mathew, Dylan Taylor
No abstract available
Patent foramen ovale (PFO) is a common cardiac anatomic variant that has been increasingly found in young (
Conclusion: In patients with CS and PFO, the likelihood of prior stroke is associated with both, PFO-related and PFO-unrelated factors.
Abstract Cardiogenic stroke (CS), characteristic causes of which include atrial fibrillation (AF) and right-to-left shunting due to a patent foramen ovale (PFO), has a well-known tendency to be associated with a more extensive ischemic area. This may result in severe neurological damage, and require strict life-long antithrombotic therapy. However, the fact that some patients have problems complying with the requirement for extended oral antithrombotic treatment has motivated the development of alternative approaches for stroke prevention. Heart structures such as the left atrial appendage (LAA) and PFO are potent...
Patent foramen ovale (PFO) is a potential cause of cryptogenic cerebrovascular events (c-CVEs). A score has been developed to identify stroke-related versus incidental PFO in c-CVEs. The Risk of Paradoxical Embolism (RoPE) score indicates that otherwise healthy young adults with a high score are likely to have pathogenic PFO.1 –3 Until recently, there was a lack of evidence for routine closure of PFO in patients who suffered from c-CVEs.4–6 However, three recent randomized studies showed a benefit of transcatheter PFO closure compared with medical therapy.
CONCLUSION: Compared with drug therapy, PFO closure reduced the risk of recurrent stroke among patients with a risk score of ≥2 and reduced the incidence of serious bleeding without increasing the risk of new-onset atrial fibrillation or atrial flutter. PMID: 32394019 [PubMed - as supplied by publisher]
ConclusionThis is a report about acromicric dysplasia with stiff skin syndrome ‐like severe cutaneous presentation caused by a single hotspot mutation, further revealing the gene pleiotropy ofFBN1.
CONCLUSION: The results do not suggest that a patent foramen ovale intervenes in the pathophysiology of the white matter lesions observed in patients with migraine. PMID: 32390130 [PubMed - in process]
Abstract BACKGROUND: Residual shunt is observed in up to 25% of patients after patent foramen ovale (PFO) closure, but its long-term influence on stroke recurrence currently is unknown. OBJECTIVE: To investigate the association of residual shunt after PFO closure with the incidence of recurrent stroke and transient ischemic attack (TIA). DESIGN: Prospective cohort study comparing stroke or TIA recurrence in patients with and without residual shunt after PFO closure. SETTING: Single hospital center. PARTICIPANTS: 1078 consecutive patients (mean age, 49.3 years) with PFO-attributable cryptogenic ...